Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases

Autoimmunity Reviews

Volumn 10, Issue 6, 2011, Pages 341-352

  Van Assen, S ^a   Elkayam, O ^b,c   Agmon Levin, N ^d   Cervera, R ^e   Doran, M F ^f   Dougados, M ^g   Emery, P ^h   Geborek, P ⁱ   Ioannidis, J P A ^j,k,l,m   Jayne, D R W ⁿ   Kallenberg, C G M ^a   Muller Ladner U ^o   Shoenfeld, Y ^c,d   Stojanovich, L ^p   Valesini, G ^q   Wulffraat, N M ^r   Bijl, M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Dana Medical Center   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e HOSPITAL CLÍNIC   (Spain)

^f ST JAMES S HOSPITAL   (Ireland)

^g université Paris Cité   (France)

^h UNIVERSITY OF LEEDS   (United Kingdom)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF IOANNINA   (Greece)

^l TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ ADDENBROOKE S HOSPITAL   (United Kingdom)

^o JUSTUS LIEBIG UNIVERSITY   (Germany)

^p UNIVERSITY OF BELGRADE   (Serbia)

^q SAPIENZA UNIVERSITY OF ROME   (Italy)

^r UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BCG VACCINE; CHOLERA VACCINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPHTHERIA VACCINE; ETANERCEPT; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; INFLIXIMAB; JAPANESE ENCEPHALITIS VACCINE; LEFLUNOMIDE; MEASLES VACCINE; METHOTREXATE; MUMPS VACCINE; MYCOPHENOLIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VACCINE; WART VIRUS VACCINE;

ADULT DISEASE; ARTICLE; AUTOIMMUNE DISEASE; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; RHEUMATIC DISEASE; SYSTEMATIC REVIEW; VACCINATION;

ADULT; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; DISEASE SUSCEPTIBILITY; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC FACTORS; OPPORTUNISTIC INFECTIONS; RHEUMATIC DISEASES; VACCINATION; VACCINES;

EID: 79953161956     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.12.003     Document Type: Article

References (161)

1. Falagas M.E., Manta K.G., Betsi G.I., Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007 May, 26(5):663-670.
2. Bosch X., Guilabert A., Pallares L., et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 2006, 15(9):584-589.
3. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002 Sep, 46(9):2287-2293.
4. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994 Apr, 37(4):481-494.
5. Cervera R., Khamashta M.A., Font J., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003 Sep, 82(5):299-308.
6. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007 Jul, 66(7):940-944.
7. Ruangjutipopan S., Kasitanon N., Louthrenoo W., Sukitawut W., Wichainun R. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai 2002 Nov, 85(11):1204-1209.
8. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992 Mar 15, 116(6):488-498.
9. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000 May, 43(5):1021-1032.
10. Little M.A., Nightingale P., Verburgh C.A., et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis Jul 1 2009.
11. Marie I., Hachulla E., Cherin P., et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005 Apr 15, 53(2):155-165.
12. van Assen S., Agmon-Levin N., Elkayam O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis Dec 3 2010.
13. Nichol K.L., Wuorenma J., von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998 Sep 14, 158(16):1769-1776.
14. Hak E., Nordin J., Wei F., et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002 Aug 15, 35(4):370-377.
15. Isenberg D.A., Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Ehrenstein M., et al. A retrospective seven-year analysis of the use of b-cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. ACR 2008, abstract 1075.
16. Yee A.M., Ng S.C., Sobel R.E., Salmon J.E. Fc gammaRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis Rheum 1997 Jun, 40(6):1180-1182.
17. Klippel J.H., Karsh J., Stahl N.I., Decker J.L., Steinberg A.D., Schiffman G. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979 Dec, 22(12):1321-1325.
18. Naveau C., Houssiau F.A. Pneumococcal sepsis in patients with systemic lupus erythematosus. Lupus 2005, 14(11):903-906.
19. Favalli E.G., Desiati F., Atzeni F., et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009 Jan, 8(3):266-273.
20. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009 Feb 18, 301(7):737-744.
21. Gordon K.B., Gottlieb A.B., Gianinni E.H., Mease P.J., Chon Y., Weng H.H., et al. Clinical trial safety data of events of interest in patients receiving etanercept (ENBREL®) across approved indications. ACR 2007, abstract 960.
22. Weinblatt M., Genovese M., Bathon J., Kremer J., Fleischmann R., Schiff M., et al. Safety and efficacy of etanercept (Enbrel®) treatment in north american patients with early and long-standing rheumatoid arthritis: 10 years of clinical experience. ACR 2008, abstract 1007.
23. Antonelli M.A., Moreland L.W., Brick J.E. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991 Mar, 90(3):295-298.
24. McDonald J.R., Zeringue A.L., Caplan L., et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009 May 15, 48(10):1364-1371.
25. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007 Dec 15, 57(8):1431-1438.
26. Speerstra F., Boerbooms A.M., van de Putte L.B., van Beusekom H.J., Kruijsen M.W., Vandenbroucke J.P. Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10years of experience. Ann Rheum Dis 1982, 41(Suppl 1):37-39.
27. Wolfe F., Michaud K., Chakravarty E.F. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006 Nov, 45(11):1370-1375.
28. Perez-Zafrilla B., Garcia Doval I., Carmona L. Rates of herpes zoster in patients with rheumatoid arthritis and treatment with TNF antagonists. Incidence rate in Biobadaser cohort in comparison with Emecar cohort. Ann Rheum Dis 2008, 67(suppl2):327.
29. Salliot C., Bombardier C., van der Heide D. Long term safety of methotrexate in rheumatoid arthritis; a systematic literature review. Ann Rheum Dis 2008, 67(suppl II):204.
30. Ginzler E., Diamond H., Kaplan D., Weiner M., Schlesinger M., Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978 Jan, 21(1):37-44.
31. Kahl L.E. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 1994 Jan, 21(1):84-86.
32. Kang T.Y., Lee H.S., Kim T.H., Jun J.B., Yoo D.H. Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. Rheumatol Int 2005 Mar, 25(2):97-102.
33. Manzi S., Kuller L.H., Kutzer J., et al. Herpes zoster in systemic lupus erythematosus. J Rheumatol 1995 Jul, 22(7):1254-1258.
34. Nagaoka S., Tani K., Ishigatsubo Y., et al. Herpes zoster in patients with polymyositis and dermatomyositis. Kansenshogaku Zasshi 1990 Nov, 64(11):1394-1399.
35. Nagasawa K., Yamauchi Y., Tada Y., Kusaba T., Niho Y., Yoshikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990 Aug, 49(8):630-633.
36. Wang F., Chua C.T., Bosco J. Herpes zoster in patients with systemic lupus erythematosus. Singapore Med J 1983 Aug, 24(4):218-220.
37. Dubois E.L., Tuffanelli D.L. Clinical manifestations of systemic lupus erythematosus. Computer analysis OF 520 cases. JAMA 1964 Oct 12, 190:104-111.
38. Ishikawa O., Abe M., Miyachi Y. Herpes zoster in Japanese patients with systemic lupus erythematosus. Clin Exp Dermatol 1999 Jul, 24(4):327-328.
39. Janwityanuchit S., Totemchokchyakarn K., Krachangwongchai K., Vatanasuk M. Infection in systemic lupus erythematosus. J Med Assoc Thai 1993 Oct, 76(10):542-548.
40. Moutsopoulos H.M., Gallagher J.D., Decker J.L., Steinberg A.D. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum 1978 Sep, 21(7):798-802.
41. Della-Torre E., Bozzolo E., Baldini M., Ferrante L., Bonavida G., Baldissera E., et al. Individualized therapy provides better outcome in patients with proliferative lupus nephritis: follow up of a cohort of Italian patients. Ann Rheum Dis 2009, 68(suppl3):247.
42. Medeiros A.C., Martin P., Ribeiro A.R., Gonçalves R., Borba E.F. Associated factors and outcome of herpes zoster in systemic lupus erythematosus (SLE) patients. ACR 2007, abstract 1950.
43. Tanaka Y., Tokunaga M., Nawata M., Suzuki K., Iwata S., Yamaoka K., et al. Long-term follow up of rituximab (anti-CD20) therapy for refractory systemic lupus erythematosus. ACR 2007, abstract 1939.
44. Pope J.E., Krizova A., Ouimet J.M., Goodwin J.L., Lankin M. Close association of herpes zoster reactivation and systemic lupus erythematosus (SLE) diagnosis: case-control study of patients with SLE or noninflammatory nusculoskeletal disorders. J Rheumatol 2004 Feb, 31(2):274-279.
45. Mak A., Tan J.Y., Su H.C., Ho R.C. Mycophenolate mofetil confers survival benefit and is safer than cyclophosphamide in the treatment of proliferative lupus nephritis: a comprehensive meta-analysis of 445 patients in 8 controlled trials. ACR 2008, abstract 1066.
46. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Rituximab in extra-renal SLE patients showed no significant difference compared to placebo at 52weeks in the randomized, double-blind phase II/III study EXPORER. Ann Rheum Dis 2009, 68(suppl3):249.
47. Wung P.K., Holbrook J.T., Hoffman G.S., et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005 Dec, 118(12):1416.
48. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005 Jul, 52(7):1986-1992.
49. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006 Sep 15, 43(6):717-722.
50. Brassard P., Lowe A.M., Bernatsky S., Kezouh A., Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009 Mar 15, 61(3):300-304.
51. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003 Aug, 48(8):2122-2127.
52. Seong S.S., Choi C.B., Woo J.H., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007 Apr, 34(4):706-711.
53. Sichletidis L., Settas L., Spyratos D., Chloros D., Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006 Oct, 10(10):1127-1132.
54. Wolfe F., Michaud K., Anderson J., Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004 Feb, 50(2):372-379.
55. Yamada T., Nakajima A., Inoue E., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006 Dec, 65(12):1661-1663.
56. Yun J.E., Lee S.W., Kim T.H., et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 2002 Mar, 20(2):127-132.
57. Allali F., Rkain H., Faik A., El Hassani S., Hajjaj-Hassouni N. Prevalence and clinical characteristics of tuberculosis in rheumatoid arthritis patients. Clin Rheumatol 2005 Nov, 24(6):656-657.
58. Askling J. Risk for tuberculosis following treatment of rheumatoid arthritis with anti-TNF therapy-the Swedish experience 1998-2008. Ann Rheum Dis 2009, 68(suppl3):422.
59. Doran J.P.W., Ng C.T., Veale D.J., Fitzgerald O., Bresnihan B. Late-onset tuberculosis infection in patients receiving anti-TNF therapy. Ann Rheum Dis 2009, 68(suppl3):423.
60. van Vollenhoven R.F., Emery P., Bingham C.O., Keystone E., Fleischmann R.M., Furst D.E., et al. Long-term safety of rituximab: follow-up of the RA clinical trials and re-treatment population. Ann Rheum Dis 2009, 68(suppl3):76.
61. van Vollenhoven R.F., Nishimoto N., Yamanaka H., Woodworth T., Schiff M.H., Taylor A., et al. Experience with mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. Ann Rheum Dis 2009, 68(suppl3):567.
62. Baronnet L., Kahn V., Lacoin C., Barnetche T., Schaeverbeke T. Tuberculosis incidence in rheumatoid arthritis affected patients. Ann Rheum Dis 2008, 67(suppl2):544.
63. Tubach F., Salmon D., Ravaud P., Lequerré T., Goupille P., Schaeverbeke T., et al. The risk of tuberculosis with anti-TNF is higher with monoclonal antibodies than with the soluble receptor. Results of the French 3-year prospective RATIO observatory. Ann Rheum Dis 2008, 67(suppl2):52.
64. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M. Specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSR Biologic Register (BSRBR). Ann Rheum Dis 2008, 67(suppl2):178. BSRBR consortium, Symmons DPMSymmons DPM.
65. Mines D., Gu Y., Liu Q., Horne L.N., Harrison M.J. Risk of active tuberculosis (TB) among biologic-naive patients: retrospective cohort study in a US claims database. Ann Rheum Dis 2008, 67(suppl2):91.
66. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Ito K., et al. Safety profile of tocilizumab in Japanese patients with rheumatoid arthritis-incidences of infections in Japanese long-term clinical studies. Ann Rheum Dis 2008, 67(suppl2):335.
67. Burmester G.R., Matuci Cerinic M., Mariette X., Navarro Blasco F., Oezer U., Unnebrink K., et al. Safety and effectiveness of adalimumab (Humira®) is maintained in patients with rheumatoid arthritis-three-year reults of REALISE, a post-marketing observational study. Ann Rheum Dis 2008, 67(suppl2):176.
68. Vadillo C., Abásolo L., Hernández C., Iajas C., Martines Prada C., Pato E., et al. Incidence of tuberculosis in patients with autoimmune disorders in a tertiary hopsital of Spain. The role of biologic drugs. ACR 2008, abstract 1448.
69. Smolen J.S., Beaulieu A.D., Dikranian A., Fenton I., Fisheleva E., Alecock E., et al. Safety of tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. ACR 2008, abstract 1669.
70. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Symmons D.P. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR. ACR 2008, abstract 1263.
71. Keystone E.C., Fleischmann R.M., Emery P., Chubick A., Dougados M.R., Baldassare A.R., et al. Efficacy and safety of repeat treatment courses of rituximab (RTX) in RA patients (pts) with inadequate response (IR) to tumor necrosis factor (TNF) inhibitors: long-term experience from the REFLEX study. ACR 2008, abstract 367.
72. Wajdula J., MacPeek D., Lin S., Hamza S., Fatenejad S. Tuberculosis incidence low in double-blind and open-label etanercept studies in patients with rheumatoid arthritis. ACR 2007, abstract 1022.
73. Burmester G.R., Mease P.J., Dijkmans B.A., Gordon K.B., Lovell D.J., Panaccione R., et al. Adalimumab safety profile in global clinical trials and reduction in standardized mortality ratios (SMR) across multiple indications. ACR 2007, abstract 959.
74. Weinblatt M.E., Keystone E.C., Furst D.E., Kavanaugh A.F., Perez J.L., Segurado O.G. Change over time in the safety, efficacy, and remission profiles of patients with rheumatoid arthritis receiving adalimumab for up to 7 years. ACR 2007, abstract 294.
75. Bernatsky S., Bombardier C., Bhamani A., Cividino A., Hux J.E., Paterson M., et al. Tuberculosis in a population-based cohort of seniors with rheumatoid arthritis. Ann Rheum Dis 2009, 68(suppl3):568.
76. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009 Jan, 68(1):25-32.
77. Kremer J.M., Russell A.S., Emery P., Abud-Mendoza C., Szechinski J., Becker J.C., et al. Abatacept demonstrates consistent safey and sustained improvements in efficacy through 5years of treatment in biologic-naive patients with RA. Ann Rheum Dis 2009, 68(suppl3):444.
78. Kim H.A., Yoo C.D., Baek H.J., et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998 Jan, 16(1):9-13.
79. Mok M.Y., Lo Y., Chan T.M., Wong W.S., Lau C.S. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol 2005 Apr, 32(4):609-615.
80. Tam L.S., Li E.K., Wong S.M., Szeto C.C. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol 2002, 31(5):296-300.
81. Balakrishnan C., Mangat G., Mittal G., Joshi V.R. Tuberculosis in patients with systemic lupus erythematosus. J Assoc Physicians India 1998 Aug, 46(8):682-683.
82. Feng P.H., Tan T.H. Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1982 Feb, 41(1):11-14.
83. Hou C.L., Tsai Y.C., Chen L.C., Huang J.L. Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared. Clin Rheumatol 2008 May, 27(5):557-563.
84. Purice S., Mitu S., Popescu T., Guran M., Vintila M., Suta G. The relationship between systemic lupus erythematosus and tuberculosis. Med Interne 1982 Jul, 20(3):191-196.
85. Rovensky J., Kovalancik M., Kristufek P., et al. Contribution to the problem of occurrence of tuberculosis in patients with systemic lupus erythematosus. Z Rheumatol 1996 May, 55(3):180-187.
86. Sayarlioglu M., Inanc M., Kamali S., et al. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 2004, 13(4):274-278.
87. Shyam C., Malaviya A.N. Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. Rheumatol Int 1996, 16(1):1-3.
88. Wang J., Pan H.F., Su H., Li X.P., Xu J.H., Ye D.Q. Tuberculosis in systemic lupus erythematosus in Chinese patients. Trop Doct 2009 Jul, 39(3):165-167.
89. Crompton G.K., Cameron S.J., Langlands A.O. Pulmonary fibrosis, pulmonary tuberculosis and ankylosing spondylitis. Br J Dis Chest 1974 Jan, 68(1):51-56.
90. Ho H.H., Lin M.C., Yu K.H., Wang C.M., Wu Y.J., Chen J.Y. Pulmonary tuberculosis and disease-related pulmonary apical fibrosis in ankylosing spondylitis. J Rheumatol 2009 Feb, 36(2):355-360.
91. Van den Bosch F., Kruithof E., Baeten D., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002 Mar, 46(3):755-765.
92. Heldmann F., Brandt J., van der Horst-Bruinsma I., Landewe R., Sieper J., Burmester G., et al. European ankylosing spondylitis infliximab cohort (EASIC): safety of longterm therapy with infliximab in patients with ankylosing spondylitis (AS). Ann Rheum Dis 2009, 68(suppl3):626.
93. Hoehle M., Finkenstaedt M., Maas R. Efficacy and safety of etanercept monotherapy in patients with ankylosing spondylitis - treatment period of >7years. Ann Rheum Dis 2009, 68(suppl68):631.
94. Sieper J., Meng T., Neeck G., Klopsch T., Loeschmann P. A drug utilisation observation (DUO) study to evaluate the safety and effectiveness of enbrel (etanercept) in patients with ankylosing spondylitis (AS). ACR 2008, abstract 1110.
95. Martin Mola E., van der Linden S., Wishneski Robertson D., Freundlich B.F., Koenig A.S. Five-year efficacy and safety, including patient-reported outcomes, with etanercept in ankylosing spondylitis. ACR 2008, abstract 1119.
96. Dijkmans B.A., Sieper J., van der Linden S., Martin-Mola E., Leirisalo-Repo M., Freundlich B., et al. Long term efficacy and safety, including reports of ocular inflammation, in ankylosing spondylitis patients treated with etanercept for 4 years. ACR 2007, abstract 1161.
97. van der Heijde D., Schiff M.H., Sieper J., Dijkmans B.A., Mease P.J., Kupper H., et al. 2-Year safety and efficacy results from the adalimumab trial evaluating long-term efficacy and safety in ankylosing spondylitis (ATLAS). ACR 2007, abstract 581.
98. van der Heijde D., Sieper J., Dijkmans B.A.C., Schiff M.H., Kivitz A., Westhovens R., et al. Three-year safety and efficacy results from the adalimumab (Humira®) trial evaluting long-term efficacy and safety in ankylosing spondylitis. Ann Rheum Dis 2008, 67(suppl2):519.
99. Jonasson F., Cullen J.F., Elton R.A. Temporal arteritis. A 14-year epidemiological, clinical and prognostic study. Scott Med J 1979 Apr, 24(2):111-117.
100. Schmidt J., Duhaut P., Smail A., Salle V., Chatelain D., Bosshard S., et al. Severe infections during giant cell arteritis and polymyalgia rheumatica course: incidence and mortality. the prospective, multicenter cohort GRACG study. ACR 2008, abstract 2015.
101. Schmidt J., Duhaut P., Smail A., Salle V., Chatelain D., Bosshard S., et al. Severe infections during giant cell arteritis (GCA) course: incidence and mortalitiy. The prospective, multicenter double cohort CRACG study. Ann Rheum Dis 2009, 68(suppl3):80.
102. Schmidt J., Duhaut P., Smail A., Salle V., Chatelain D., Bosshard S., et al. Survival and causes of death in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR): the prospective, multicenter double cohort CRACG study. Ann Rheum Dis 2009, 68(suppl3):600.
103. Tam L.S., Chan A.Y., Chan P.K., Chang A.R., Li E.K. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004 Nov, 50(11):3619-3625.
104. Lee Y., Choe J., Kim J., Park Y., Lee S., Kang Y., et al. Prevalence and risk factors for human papillomavirus infection and cervical cytological abnormalities in Korean patients with systemic lupus erythematosus. ACR 2007, abstract 1105.
105. Nath R., Mant C., Luxton J., et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007 May 15, 57(4):619-625.
106. Tam L., Chan P.S., Ho S., Cheung T., Yim S., Wong M.C., et al. Natural history of cervical human papillomavirus infection among women with systemic lupus erythematosus. Ann Rheum Dis 2009, 68(suppl3):128.
107. Lee Y., Choe J., Kim J., Park Y., Lee S., Kang Y., et al. Prevalence and risk factors for human papillomavirus infection and cervical cytological abnormalities in Korean patients with systemic lupus erythematosus. ACR 2007, abstract 1105.
108. Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 2006 Jun, 13(2-4):373-375.
109. Chalmers A., Scheifele D., Patterson C., et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994 Jul, 21(7):1203-1206.
110. Del Porto F., Lagana B., Biselli R., et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006 Apr 12, 24(16):3217-3223.
111. Denman E.J., Denman A.M., Greenwood B.M., Gall D., Heath R.B. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis 1970 May, 29(3):220-231.
112. Elkayam O., Bashkin A., Mandelboim M., et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2009 Feb, 24.
113. Fomin I., Caspi D., Levy V., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006 Feb, 65(2):191-194.
114. Gelinck L.B., van der Bijl A.E., Beyer W.E., et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008 May, 67(5):713-716.
115. Herron A., Dettleff G., Hixon B., et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 1979 Jul 6, 242(1):53-56.
116. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007 Feb, 34(2):272-279.
117. Kubota T., Nii T., Nanki T., et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007, 17(6):531-533.
118. Nii T., Kubota T., Nanki T., et al. Reevaluation of antibody titers 1year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. Mod Rheumatol 2009, 19(2):216-218.
119. Turner-Stokes L., Cambridge G., Corcoran T., Oxford J.S., Snaith M.L. In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis 1988 Jul, 47(7):532-535.
120. van Assen S., Holvast A., Benne C.A., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2009 Dec 28, 62(1):75-81.
121. Kapetanovic M.C., Saxne T., Nilsson J.A., Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007 Apr, 46(4):608-611.
122. Gelinck L.B., Teng Y.K., Rimmelzwaan G.F., van den Bemt B.J., Kroon F.P., van Laar J.M. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007 Oct, 66(10):1402-1403.
123. Oren S., Mandelboim M., Braun-Moscovici Y., et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008 Jul, 67(7):937-941.
124. Williams G.W., Steinberg A.D., Reinertsen J.L., Klassen L.W., Decker J.L., Dolin R. Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med 1978 Jun, 88(6):729-734.
125. Holvast A., Huckriede A., Wilschut J., et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006 Jul, 65(7):913-918.
126. Mercado U., Acosta H., Avendano L. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin 2004 Jan, 56(1):16-20.
127. Wiesik-Szewczyk E., Romanowska M., Mielnik P., et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol 2010 Jun, 29(6):605-613.
128. Brodman R., Gilfillan R., Glass D., Schur P.H. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 1978 Jun, 88(6):735-740.
129. Louie J.S., Nies K.M., Shoji K.T., et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978 Jun, 88(6):790-792.
130. Pons V.G., Reinertsen J.L., Steinberg A.D., Dolin R. Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J Med Virol 1979, 4(1):15-23.
131. Ristow S.C., Douglas R.G., Condemi J.J. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978 Jun, 88(6):786-789.
132. Abu-Shakra M., Press J., Varsano N., et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002 Dec, 29(12):2555-2557.
133. Holvast A., Stegeman C.A., Benne C.A., et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009 Jun, 68(6):873-878.
134. Zycinska K., Romanowska M., Nowak I., Rybicka K., Wardyn K.A., Brydak L.B. Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis. J Physiol Pharmacol 2007 Nov, 58 Suppl 5(Pt 2):819-828.
135. Setti M., Fenoglio D., Ansaldi F., et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009 May 26, 27(25-26):3367-3372.
136. Gelinck L.B., van der Bijl A.E., Visser L.G., et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 2008 Jun 25, 26(27-28):3528-3533.
137. Visvanathan S., Keenan G.F., Baker D.G., Levinson A.I., Wagner C.L. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007 May, 34(5):952-957.
138. Kapetanovic M.C., Saxne T., Sjoholm A., Truedsson L., Jonsson G., Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006 Jan, 45(1):106-111.
139. Bingham C.O., Looney R.J., Deodhar A., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis Rheum 2009 Dec 28, 62(1):64-74.
140. Elkayam O., Paran D., Caspi D., et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002 Jan 15, 34(2):147-153.
141. Elkayam O., Caspi D., Reitblatt T., Charboneau D., Rubins J.B. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004 Feb, 33(4):283-288.
142. Croft S.M., Schiffman G., Snyder E., Herrmann K., James K., Jarrett M.P. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus. J Rheumatol 1984 Apr, 11(2):141-146.
143. Lipnick R.N., Karsh J., Stahl N.I., Blackwelder W.C., Schiffman G., Klippel J.H. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 1985 Dec, 12(6):1118-1121.
144. Jarrett M.P., Schiffman G., Barland P., Grayzel A.I. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. Arthritis Rheum 1980 Nov, 23(11):1287-1293.
145. McDonald E., Jarrett M.P., Schiffman G., Grayzel A.I. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984 Jun, 11(3):306-308.
146. Tarjan P., Sipka S., Marodi L., et al. No short-term immunological effects of Pneumococcus vaccination in patients with systemic lupus erythematosus. Scand J Rheumatol 2002, 31(4):211-215.
147. Battafarano D.F., Battafarano N.J., Larsen L., et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998 Oct, 41(10):1828-1834.
148. Franco Salinas G., de Rycke L., Cantaert T., Remans P., van der Burg M., Barendregt B., et al. TNF blockade impairs T cell dependent antibody responses. Ann Rheum Dis 2009, 68(suppl3):238.
149. Mease P.J., Ritchlin C.T., Martin R.W., et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004 Jul, 31(7):1356-1361.
150. Mercado U., Acosta H., Diaz-Molina R. Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis. J Rheumatol 2009 Jul, 36(7):1549-1550.
151. Elkayam O., Yaron M., Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002 Jul, 61(7):623-625.
152. Kuruma K.A., Borba E.F., Lopes M.H., de Carvalho J.F., Bonfa E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007, 16(5):350-354.
153. Erkek E., Ayaslioglu E., Erkek A.B., Kurtipek G.S., Bagci Y. Response to vaccination against hepatitis B in patients with Behcet's disease. J Gastroenterol Hepatol 2005 Oct, 20(10):1508-1511.
154. Devey M.E., Bleasdale K., Isenberg D.A. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1987 Jun, 68(3):562-569.
155. Abe T., Homma M. Immunological reactivity in patients with systemic lupus erythematosus. Humoral antibody and cellular immune responses. Acta Rheumatol Scand 1971, 17(1):35-46.
156. Kashef S., Ghazizadeh F., Derakhshan A., Farjadian S., Alyasin S. Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran J Immunol 2008 Sep, 5(3):181-184.
157. Nies K., Boyer R., Stevens R., Louie J. Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses. Arthritis Rheum 1980 Dec, 23(12):1343-1350.
158. Stassen P.M., Sanders J.S., Kallenberg C.G., Stegeman C.A. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2008 Feb, 23(2):654-658.
159. Elkayam O., Paran D., Burke M., et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 2005 Nov, 38(7):493-496.
160. Karsh J., Pavlidis N., Schiffman G., Moutsopoulos H.M. Immunization of patients with Sjogren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. Arthritis Rheum 1980 Nov, 23(11):1294-1298.
161. Holvast A., van Assen S., de Haan A., et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford) 2009 Oct, 48(10):1294-1299.